NO911690L - Produkter og fremgangsmaate for aa kontrollere suppresjon av den neoplastiske fenotypen. - Google Patents

Produkter og fremgangsmaate for aa kontrollere suppresjon av den neoplastiske fenotypen.

Info

Publication number
NO911690L
NO911690L NO91911690A NO911690A NO911690L NO 911690 L NO911690 L NO 911690L NO 91911690 A NO91911690 A NO 91911690A NO 911690 A NO911690 A NO 911690A NO 911690 L NO911690 L NO 911690L
Authority
NO
Norway
Prior art keywords
suppression
procedures
check
products
gene
Prior art date
Application number
NO91911690A
Other languages
English (en)
Other versions
NO314222B1 (no
NO911690D0 (no
Inventor
Wen-Hwa Lee
Huei-Jen Su Huang
Eva Y H P Lee
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23012037&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO911690(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Publication of NO911690D0 publication Critical patent/NO911690D0/no
Publication of NO911690L publication Critical patent/NO911690L/no
Publication of NO314222B1 publication Critical patent/NO314222B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4736—Retinoblastoma protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
NO19911690A 1988-10-31 1991-04-29 Fremgangsmåte for fremstilling av en rekombinant viral partikkel for suppresjon av en neoplastisk fenotype NO314222B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26582988A 1988-10-31 1988-10-31
PCT/US1989/004808 WO1990005180A1 (en) 1988-10-31 1989-10-30 Products and methods for controlling the suppression of the neoplastic phenotype

Publications (3)

Publication Number Publication Date
NO911690D0 NO911690D0 (no) 1991-04-29
NO911690L true NO911690L (no) 1991-06-25
NO314222B1 NO314222B1 (no) 2003-02-17

Family

ID=23012037

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19911690A NO314222B1 (no) 1988-10-31 1991-04-29 Fremgangsmåte for fremstilling av en rekombinant viral partikkel for suppresjon av en neoplastisk fenotype

Country Status (9)

Country Link
EP (2) EP0792931A3 (no)
JP (1) JPH03505675A (no)
AT (1) ATE161039T1 (no)
AU (3) AU638954B2 (no)
CA (1) CA2001815C (no)
DE (1) DE68928491T2 (no)
FI (1) FI113377B (no)
NO (1) NO314222B1 (no)
WO (1) WO1990005180A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384735B1 (en) 1986-08-11 2008-06-10 Massachusetts Eye And Ear Infirmary Retinoblastoma nucleic acids
US7223842B1 (en) 1986-08-11 2007-05-29 Massachusetts Eye And Ear Infirmary Detection of proteins whose absence is associated with a neoplasm
US5851991A (en) * 1987-08-31 1998-12-22 The Regents Of The University Of California Therapeutic use of the retinoblastoma susceptibility gene product
US7105156B1 (en) 1987-09-17 2006-09-12 The Regents Of The University Of California Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells
KR970005049B1 (ko) * 1990-07-16 1997-04-11 더 리젠츠 오브 더 유니벌시티 오브 캘리포니아 바쿨로비루스 발현 시스템, 이 벡터 시스템을 포함하는 이종성 무척추동물 숙주세포, 상기 시스템에 의해 생산되는 가용성의 정제된 야생형 망막아세포종 폴리펩티드 및 이 폴리펩티드의 생산 방법
US5569824A (en) * 1991-01-04 1996-10-29 Baylor College Of Medicine Transgenic mice containing a disrupted p53 gene
ES2158847T3 (es) * 1991-01-16 2001-09-16 Univ Johns Hopkins Mutaciones heredadas y somaticas del gen apc en el cancer colorectal del hombre.
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
WO1992015680A1 (en) 1991-03-06 1992-09-17 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5330892A (en) * 1991-03-13 1994-07-19 The Johns Hopkins University MCC gene (mutated in colorectal cancer) used for diagnosis of cancer in humans
JP3151054B2 (ja) * 1992-06-25 2001-04-03 協和醗酵工業株式会社 抗ｄｃｃ遺伝子産物モノクローナル抗体
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
US5756668A (en) * 1994-11-15 1998-05-26 The Johns Hopkins University School Of Medicine Hypermethylated in cancer polypeptide, HIC-1
JPH10509879A (ja) * 1994-11-28 1998-09-29 ジェネティック セラピー， インコーポレイテッド 複製欠陥ベクターを用いる、組織特異的処置、診断方法、および組成物
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
HUP0004240A2 (en) * 1997-10-25 2001-03-28 Roche Diagnostics Gmbh Suspension packing cell lines for retrovirus vestors
FR2843526A1 (fr) * 2002-08-16 2004-02-20 Inst Nat Sante Rech Med Utilisation d'animaux heterozygotes cdx2+/-pour tester des factures cancerogenes ou anti-cancereux
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US11311574B2 (en) 2003-08-08 2022-04-26 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4736866A (en) * 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US4942123A (en) * 1987-09-17 1990-07-17 The Regents Of The University Of California ppRB110 -phosphoprotein the retinoblastoma susceptibility gene product

Also Published As

Publication number Publication date
FI113377B (fi) 2004-04-15
NO314222B1 (no) 2003-02-17
EP0440744A1 (en) 1991-08-14
DE68928491D1 (de) 1998-01-22
EP0440744B1 (en) 1997-12-10
DE68928491T2 (de) 1998-06-04
WO1990005180A1 (en) 1990-05-17
NO911690D0 (no) 1991-04-29
EP0792931A3 (en) 1999-05-19
AU4635089A (en) 1990-05-28
CA2001815A1 (en) 1990-04-30
AU638954B2 (en) 1993-07-15
AU4915593A (en) 1994-01-13
CA2001815C (en) 2002-09-03
EP0440744A4 (en) 1992-07-01
ATE161039T1 (de) 1997-12-15
EP0792931A2 (en) 1997-09-03
AU670624B2 (en) 1996-07-25
AU7042196A (en) 1997-02-20
FI911997A0 (fi) 1991-04-25
JPH03505675A (ja) 1991-12-12

Similar Documents

Publication Publication Date Title
NO911690D0 (no) Produkter og fremgangsmaate for aa kontrollere suppresjon av den neoplastiske fenotypen.
DE3750135T2 (de) Textverarbeitungssystem und -verfahren zur Prüfung des richtigen und folgerichtigen Gebrauchs von Einheiten und chemischen Formeln in einem Textverarbeitungssystem.
ATE295899T1 (de) Screeningverfahren für die aktivität von agenzien unter verwendung von teleosten
DE3853014T2 (de) Apparat zur Prüfung von Einkäufen.
NO871253L (no) Fremgangsmaate og anordning ved hovedsakelig roer- eller slangeformede brannbeskyttede gjenstander.
ZA904842B (en) Novel methods of treatment using ranolazine and related piperazine derivatives
DE69003607T2 (de) Vorrichtung zum Agglomerieren und Beschichten und Agglomerier- und Beschichtungsverfahren unter Verwendung der Vorrichtung.
NO881355D0 (no) Fremgangsmaate og apparat til aa undertrykke eksplosjoner og branner.
UA6035A1 (uk) Засіб для визначення лейкоцітів в сечі
ATE38036T1 (de) Benzothiophenderivate als bronchodilatoren.
ATE77817T1 (de) 3-cyan-pyridine, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung.
AU7564396A (en) Rac-proteine kinase as therapeutic agent or in diagnostics
DK388488A (da) Benzolthiophenderivater og fremgangsmaade til fremstilling deraf
NO855206L (no) Fremgangsmaate og apparat for regulering av vaeskenivaa.
NO880882D0 (no) Fremgangsmaate og middel for bestemmelse av hyaluronsyre.
DE3880956D1 (de) Verfahren und vorrichtung zum regeln des herstellens von glasfasern.
NO901045L (no) Fremgangsmaate og apparat for epitermisk noeytron-desintegrasjonslogging.
DE68920757T2 (de) Lysyl-Oxidase-Inhibitoren.
NO173745C (no) Garvemiddel og fremgangsmaate for garving av dyrehuder
NO174728C (no) Fremgangsmåte og apparat for brönnlogging.
ES2058274T3 (es) Un metodo para expresar un producto genico heterologo no bacteriano.
FR2656331B1 (fr) Procede de culture cellulaire permettant le test notamment de substances liposolubles et de produits finis.
DE3751158D1 (de) System zur Anwesenheitsprüfung von Artikeln in frei zugänglichen Verkaufsapparaten.
NO162739C (no) Fremgangsmaate og innretning for kvantitativ besemmelse avhemoglobinnivaaet i en biologisk proeve.
HUT34950A (en) Process for the production of alpha-allene-alpha-amino acids and of therapeutic preparations containing such agents